Bicara Therapeutics Inc. Common Stock
BCAXNASDAQHealthcare● Active
$20.14
+$0.14(+0.70%)
Market Cap$1.1B
P/E Ratio—
52W High$24.25
52W Low$8.48
Bicara Therapeutics Inc. Common Stock (BCAX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BCAX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.93
Est. -$0.64 · -45.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
BCAX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.78 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.64 | -$0.93 | -45.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.72 | -$0.68 | +5.6% | — | — | — |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.55 | -$0.67 | -21.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.54 | -$0.50 | +7.4% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.40 | -$0.68 | -70.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.31 | -$0.39 | -25.8% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.46 | -$1.60 | -247.8% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.78
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.93
EPS Est.
-$0.64
EPS Surpr.
-45.3%
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.68
EPS Est.
-$0.72
EPS Surpr.
+5.6%
Revenue
—
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.67
EPS Est.
-$0.55
EPS Surpr.
-21.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.50
EPS Est.
-$0.54
EPS Surpr.
+7.4%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.68
EPS Est.
-$0.40
EPS Surpr.
-70.0%
Revenue
—
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.39
EPS Est.
-$0.31
EPS Surpr.
-25.8%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$1.60
EPS Est.
-$0.46
EPS Surpr.
-247.8%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.02 | $-1.02 | $-1.02 | 3 |
| Q3 FY2027 | $-0.98 | $-0.98 | $-0.98 | 4 |
| Q2 FY2027 | $-1.00 | $-1.00 | $-1.00 | 3 |
| Q1 FY2027 | $-0.95 | $-0.95 | $-0.95 | 3 |
| Q4 FY2026 | $-0.90 | $-0.90 | $-0.90 | 7 |
| Q3 FY2026 | $-1.04 | $-0.85 | $-0.52 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -45.3% | $22.58 | $22.92 | +1.51% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +5.6% | $18.68 | $18.92 | +1.28% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -21.8% | $14.64 | $13.93 | -4.85% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +7.4% | $9.99 | $10.47 | +4.80% |
| ▼ Q2 FY2025 | May 13, 2025 | -70.0% | $14.19 | $13.04 | -8.10% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -25.8% | $13.10 | $13.40 | +2.29% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -247.8% | $24.11 | $22.35 | -7.30% |
| — Q3 FY2024 | Sep 13, 2024 | — | No price data | $23.41 | — |
Q2 FY2026+1.51%
Report Date
May 11, 2026
EPS Beat/Miss
-45.3%
Price Before
$22.58
Price After
$22.92
Q1 FY2026+1.28%
Report Date
Mar 26, 2026
EPS Beat/Miss
+5.6%
Price Before
$18.68
Price After
$18.92
Q4 FY2025-4.85%
Report Date
Nov 10, 2025
EPS Beat/Miss
-21.8%
Price Before
$14.64
Price After
$13.93
Q3 FY2025+4.80%
Report Date
Aug 12, 2025
EPS Beat/Miss
+7.4%
Price Before
$9.99
Price After
$10.47
Q2 FY2025-8.10%
Report Date
May 13, 2025
EPS Beat/Miss
-70.0%
Price Before
$14.19
Price After
$13.04
Q1 FY2025+2.29%
Report Date
Mar 27, 2025
EPS Beat/Miss
-25.8%
Price Before
$13.10
Price After
$13.40
Q4 FY2024-7.30%
Report Date
Nov 12, 2024
EPS Beat/Miss
-247.8%
Price Before
$24.11
Price After
$22.35
Q3 FY2024—
Report Date
Sep 13, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$23.41
Avg Beat Reaction+3.04%
Avg Miss Reaction-3.29%
Beat Rate2 / 8 quarters
Largest Move-8.10% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BCAX ends December
Bicara Therapeutics Inc. Common Stock (BCAX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.93 — missing the analyst consensus of $-0.64 by -45.3%. The next BCAX earnings date is expected around September 1, 2026.
Each quarter, investors track BCAX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCAX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BCAX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BCAX earnings · 5 questionsBicara Therapeutics Inc. Common Stock's next earnings report is expected around September 1, 2026. BCAX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCAX historically reports after market close (AMC).
BCAX earnings datewhen is BCAX earningsBCAX next earnings datewhen does BCAX report earningsBCAX earnings calendar
▸ Source: FMP · Bicara Therapeutics Inc. Common Stock SEC filings · US GAAP · Bicara Therapeutics Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026